Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Cell and gene therapies have redefined what’s possible in modern medicine, but their road to market is anything but straightforward.

Bioprocessing

Many biotech teams are sprinting to create breakthrough therapies, but often encounter the intricate and numerous challenges of CMC development.

Bioprocessing

What happens when the charging elephant of biotech—antibody-drug conjugates (ADCs)—meets the organizational complexity of a 300-strong analytical powerhouse?

Bioprocessing

Antibody-drug conjugates (ADCs) are generating serious buzz in biotech corridors, offering a precision-guided missile against cancer while minimizing collateral damage.

Bioprocessing

A common misconception among many researchers and biotech startup founders is that bioprocess development is straightforward.

Bioprocessing

For too long, biotech innovators have viewed biological systems as inherently messy, unpredictable, and full of “black box” mysteries.

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

You may have the next blockbuster molecule in your pipeline.

Biotech Success

Many bioproduction development projects fail due to inadequate stakeholder engagement.

Biotech Success

Lars Brandén has travelled an uncommon route from a youthful fascination with viruses to leading biology at Kolibri, a Paris-based company developing acoustic bioreactors and novel transfection chemistries.

Biotech Success

I want to let you in on a secret. Truly transformative bioprocess development is not just about creative brainstorming in the lab.

Biotech Success

Biomanufacturing has evolved from producing simple recombinant hormones to assembling highly complex biologics in living systems.

Biotech Success

Bringing a new therapeutic biologic from discovery to clinic is a delicate balancing act of cutting‑edge science, tight regulatory timelines, and rapid iteration. One misalignment—whether in documentation, communication, or data interpretation—can quickly derail months of hard work.

Innovation

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

Innovation

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Innovation

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?

Innovation

Why hasn’t DMSO been dethroned—and what’s finally threatening its reign?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.